ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $12.50.

ALXO has been the subject of several recent research reports. Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Finally, UBS Group decreased their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th.

ALX Oncology Stock Up 12.2 %

Shares of NASDAQ ALXO opened at $1.66 on Thursday. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83. The stock has a market cap of $87.55 million, a P/E ratio of -0.56 and a beta of 1.03. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The business’s fifty day simple moving average is $1.54 and its 200-day simple moving average is $4.37.

Institutional Investors Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co purchased a new position in shares of ALX Oncology during the first quarter worth about $27,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after buying an additional 5,200 shares during the period. SG Americas Securities LLC lifted its stake in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology in the second quarter valued at approximately $63,000. Finally, GSA Capital Partners LLP purchased a new position in shares of ALX Oncology during the third quarter worth approximately $88,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.